[exclusive] the National Health Insurance Bureau conducts intensive research in various places. Please don't think about it!

Recently, according to media reports, Hu Jinglin, director of the state health insurance bureau, went to Shanghai to carry out work research, on-the-spot visit to the municipal health insurance center, the medical centralized bidding and procurement management office, the medical insurance supervision and Inspection Institute and other units, to learn more about the bidding and procurement of drugs, the construction of medical insurance informatization and fund supervision At present, it is required to carefully organize the pilot work of centralized drug purchase and push the drug price down through volume purchase Therefore, there is a voice that when the health insurance bureau investigates Shanghai, Shanghai will become a "wind vane" and Shanghai will become a new "model" Here, the author "pours a basin of cold water" on those who hold this view Everyone must be calm Many things are neither as simple as we think nor as complex as we think Let's first figure out the public action routes after the establishment of the medical insurance bureau: on June 15, Hu Jinglin, the head and director of the newly established national medical insurance bureau, and his party went to Sanming, Fujian Province for research ——In early July, the movie "I'm not the God of medicine" was released Some places start to show in advance ——Around July 8, a notice on carrying out provincial-level special centralized procurement of anticancer drugs (Draft for comments) began to circulate in the industry All provinces are required to issue a special procurement plan for anticancer drugs by the end of August this year, launch a comprehensive special procurement work by the end of September, and complete the special procurement work by the end of this year The price of Internet, purchase, clinical use and terminal are all in place, benefiting patients ——Xinhua news agency, Beijing, July 11, 2010, the central leadership in the afternoon of the National Medical Security Bureau survey and chaired a symposium ——On July 12, the previously withdrawn leading group of the State Council on deepening the reform of the medical and health system was adjusted, and relevant notices and personnel composition structure were released to the public ——From July 31 to August 1, Hu Jinglin, director of the State Medical Security Bureau, went to Shanghai to carry out work investigation ——In the industry, a notice on convening a symposium on centralized drug procurement issued by the state health insurance bureau was circulated According to the notice, the symposium will be held on August 3, which will introduce the basic ideas and implementation plans of the pilot drug centralized procurement organized by the state, listen to local opinions and make plans for the near future work After reading the above general road map, if people with normal judgment ability are the same as the author, they will come to the following basic conclusion: the National Health Insurance Bureau has just been set up, facing a lot of waste, the first director comes from the financial system, who is engaged in financial work, and works strictly, pays attention to analyzing the logical relationship and context of things, especially in contact with the emerging After the field, it is not easy to make a conclusion Before a decision is made, it is often considered carefully and a large-scale discussion and research will be conducted Specifically, under the new situation, as an important function of the medical insurance bureau, the centralized purchase of drugs must be well integrated with the top-level design and actual combat ability Among them, Fujian, Anhui, Guangdong and Shanghai all have their own characteristics: the joint price Limited sunshine purchase of Fujian drugs based on medical insurance payment, which has experienced the baptism of the ten standards, has created the "provincial shortlist, regional bargaining" Anhui, the pioneer of "double envelope", Guangdong drug exchange with the third-party drug electronic trading platform as the main body, and Shanghai, the first trial drug third-party evaluation system in China, have different latitude and angle characteristics and highlights in terms of medical insurance payment, procurement innovation, market transaction and clinical drug selection I remember that in 1941, Mao Zedong, who had arrived in Yan'an, wrote in the preface of the book rural investigation: "without full enthusiasm, no determination to look down, no desire to learn, no putting down the stinky shelf, when the spirit of primary school students, it must not be done, it must not be done well." Therefore, the relevant parties are familiar with the true meaning of "no research, no right to speak" The medical insurance bureau has just been set up to study in Fujian and Shanghai, learn from, summarize experience, discuss problems and make centralized decisions This is the normal work before deployment decision-making, which does not mean that where to go is the benchmark, where to go is the wind direction Before analyzing the problem, our relevant industry personnel, including all aspects of pharmaceutical enterprises, may as well use their brains and transpose their positions to think about what the purpose of doing this is to make rational speech However, just at the beginning of the establishment of the medical insurance bureau, there was a great heat of the movie "I am not the God of medicine" There is a way: the army has not moved, public opinion first " To some extent, the author speculates that the attention paid to anticancer drugs has, on the one hand, slightly adjusted the relevant rhythm of the established planning of drug procurement by the medical insurance bureau, but on the other hand, from the perspective of the special procurement of anticancer drugs, it has the practical nature of "combining point and area, point and area" for the medical insurance bureau At the same time, the anticancer drugs Compared with the previous national level negotiations on drugs, this special purchase of anticancer drugs is undoubtedly more clear in terms of path, objective and risk Don't do it at this time, but when Therefore, we can see that there are a large number of drafts for consultation on relevant procurement, and the prices of local anti-cancer drug procurement are falling one after another When people gather together, the strength of one mind can often gather strength to break the gold As for drug bidding, will it be abolished? The author believes that in the new situation of price reduction, drug bidding will not be abolished, but will be further strengthened But the premise of strengthening is diversification That is, on the basis of continuing to adhere to and improve article 7, Article 70 and Article 17 of the State Council, it is not ruled out that it will continue to adhere to the principle of "taking the province (city) as the unit, making clear that the medical institution is the main body of procurement, implementing the integration of bidding and procurement, procurement with quantity, linking quantity and price, and exchanging quantity for price" On this premise, it will strengthen the pilot drug procurement, so as to form the drug procurement A new breakthrough In the future, the provincial trading center will only examine the economic and technical bid of drugs, and the decision-making power of the commercial bid will gradually and transitional move down In the future, there will be the following six procurement methods 1 Hospital (Medical Association) joint volume purchasing 2 Pharmaceutical Group Purchasing 3 Cross regional and inter provincial joint purchasing 4 Pilot cities explore special purchasing 5 Pharmaceutical exchange mode purchasing 6 Normalization matching and record purchasing In the future, we will continue to adhere to the "four favorable" route throughout drug procurement (to break the mechanism of supplementing medicine with drugs, accelerate the reform of public hospitals, especially county-level public hospitals; to reduce the false high price of drugs, reduce the burden of drug use of the people; to prevent and curb corruption in the field of drug purchase and sale, resist commercial bribery; to promote drug production and circulation Enterprise integration and reorganization, fair competition, and healthy development of the pharmaceutical industry However, the rational voice tells us that the establishment of the medical insurance bureau has a sustainable and positive impact on the overall planning of the whole medical industry, including accelerating the reform of medical fitness At the same time, it reduces the cross management of multiple departments and improves the work efficiency However, it is neither realistic nor true to put all the burden of breaking the medical reform such as "supporting doctors with drugs" on the medical insurance bureau Therefore, on July 12, the previously withdrawn leading group of the State Council on deepening the reform of the medical and health system was adjusted, and the leading group continued to be responsible for the relevant strategic guidance work of medical reform The author speculates that at this stage of all kinds of phenomena, the medical insurance bureau will not do "big break and big establishment" things, "inheritance, improvement, innovation" is a more pragmatic way of thinking (the above analysis is only for reference)